Not rendering correctly? View this email as a web page here.

 

Dear colleagues and friends,

This year has been truly great for ESMO, and I wish to personally thank you for your involvement and support. Just under a year ago I shared my vision with you about ESMO’s future in facilitating, improving and protecting clinical cancer research in Europe. This end of year letter is the right time to show the progress we’ve made on this front with evidence-based results and concrete actions.

Horizon 2020
Our first step in this process was to identify research interests and needs of ESMO members via the Horizon 2020 survey. The input you provided enabled us to understand that one way ESMO can support researchers is by centralising the much-needed practical information.

European Clinical Research Forum
An essential piece of the research puzzle is collaboration, and I’m happy to report that we have identified partners, established roles, found common ground, and agreed priority actions.

In October, ESMO and EORTC organised the first Clinical Cancer Research Forum where 65 representatives from European and International research groups, umbrella organisations, societies, national groups and cancer centres met to establish a consensus on areas of common interest and develop an action plan.  This Forum is a move towards the development of a viable research community and agreement about how all stakeholders can work together. Working groups will be formed early next year and starting 2015 the Forum will take place on a regular basis.

Research section on esmo.org
I am very pleased to announce that you can now find a fantastic new Research section on our website dedicated to the essential and practical information for anyone interested in research:

This new addition to our website is a useful resource and positions ESMO as an important facilitator in the research field.


EU Research Funding Webinar

The interest in the ESMO Webinar on EU Research Funding Opportunities (held on 24 November) was proof of the need for more information in this area. Quite soon we will have the recording of the webinar online for those of you who were not able to participate.

In closing, the clinical cancer research landscape is rapidly evolving and ESMO is keeping up with this fast pace.  High-quality research is knowledge that translates into best practice which has a real potential to improve patient outcome.

I am very proud of all we’ve achieved together this year. I wish you a wonderful holiday season, and look forward to a new year of exciting projects and continued collaboration with you.

Sincerely,
Rolf A. Stahel
ESMO President 2014-2015